Tilray Brands (NASDAQ: TLRY) shares gained 5% following new research from the University of Georgia and University of Colorado, which found that states with lenient cannabis laws experienced a significant average reduction of 16% in opioid prescriptions between 2007 and 2020. This study bolsters the case for cannabis's medical utility and strengthens arguments for federal legalization, a development considered crucial for the broader growth and profitability of cannabis companies like Tilray, which are currently constrained by fragmented state-level regulations.
New research from the University of Georgia and University of Colorado indicates that states with lenient cannabis laws saw an average 16% reduction in opioid prescriptions between 2007 and 2020, with some states reaching 22%. This finding significantly strengthens the medical utility case for cannabis as a potential alternative to addictive opioids. Tilray Brands (TLRY) shares responded positively to this external development, climbing 5% on Wednesday and outperforming the S&P 500's 0.4% gain. This movement was driven by broader industry sentiment rather than any proprietary company news. The study provides further justification for federal cannabis law reform, which is crucial for the long-term growth and profitability of the struggling cannabis sector. The current fragmented state-level legalization system is identified as a significant impediment to industry expansion. Investors should note that while this news is positive for the sector, Tilray's gain was externally driven, and a prominent analyst team did not include TLRY in its top stock recommendations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
